NASDAQ:ISPC iSpecimen (ISPC) Stock Price, News & Analysis $3.00 +0.04 (+1.35%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About iSpecimen Stock (NASDAQ:ISPC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iSpecimen alerts:Sign Up Key Stats Today's Range$2.98▼$3.9750-Day Range$2.92▼$6.3052-Week Range$2.76▼$12.20Volume2.42 million shsAverage Volume212,281 shsMarket Capitalization$2.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewiSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.Read More… iSpecimen Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks18th Percentile Overall ScoreISPC MarketRank™: iSpecimen scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for iSpecimen. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of iSpecimen is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iSpecimen is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiSpecimen has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.05% of the float of iSpecimen has been sold short.Short Interest Ratio / Days to CoveriSpecimen has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iSpecimen has recently decreased by 56.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiSpecimen does not currently pay a dividend.Dividend GrowthiSpecimen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.05% of the float of iSpecimen has been sold short.Short Interest Ratio / Days to CoveriSpecimen has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iSpecimen has recently decreased by 56.80%, indicating that investor sentiment is improving significantly. News and Social Media1.6 / 5News SentimentN/A News SentimentiSpecimen has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for iSpecimen this week, compared to 0 articles on an average week.Search Interest1 people have searched for ISPC on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, iSpecimen insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.62% of the stock of iSpecimen is held by institutions.Read more about iSpecimen's insider trading history. Receive ISPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter. Email Address ISPC Stock News HeadlinesiSpecimen Appoints Yuying Liang as CFO and Unveils Strategic Initiatives for 2025December 22 at 4:13 AM | americanbankingnews.comiSpecimen Strengthens Leadership and Expands Cancer Research FocusDecember 20 at 6:07 PM | tipranks.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… December 22, 2024 | Crypto 101 Media (Ad)iSpecimen Appoints Robert Lim as New CEODecember 12, 2024 | markets.businessinsider.comiSpecimen Inc. Reports Earnings Amid Financial ChallengesNovember 9, 2024 | markets.businessinsider.comiSpecimen Reports Third Quarter 2024 ResultsNovember 8, 2024 | markets.businessinsider.comiSpecimen releases cancer biospecimen offeringNovember 8, 2024 | markets.businessinsider.comiSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 AnnuallyNovember 7, 2024 | globenewswire.comSee More Headlines ISPC Stock Analysis - Frequently Asked Questions How have ISPC shares performed this year? iSpecimen's stock was trading at $0.5006 at the beginning of the year. Since then, ISPC stock has increased by 499.3% and is now trading at $3.00. View the best growth stocks for 2024 here. How were iSpecimen's earnings last quarter? iSpecimen Inc. (NASDAQ:ISPC) issued its earnings results on Tuesday, August, 6th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.09. The firm earned $2.86 million during the quarter. iSpecimen had a negative net margin of 91.66% and a negative trailing twelve-month return on equity of 139.25%. When did iSpecimen IPO? iSpecimen (ISPC) raised $20 million in an IPO on Thursday, June 17th 2021. The company issued 2,200,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of iSpecimen? Shares of ISPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of iSpecimen own? Based on aggregate information from My MarketBeat watchlists, some other companies that iSpecimen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and Braze (BRZE). Company Calendar Last Earnings8/06/2024Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:ISPC CUSIPN/A CIK1558569 Webispecimen.com Phone781-301-6700FaxN/AEmployees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,100,000.00 Net Margins-91.66% Pretax Margin-91.65% Return on Equity-139.25% Return on Assets-73.97% Debt Debt-to-Equity RatioN/A Current Ratio0.74 Quick Ratio0.74 Sales & Book Value Annual Sales$10.39 million Price / Sales0.28 Cash FlowN/A Price / Cash FlowN/A Book Value$21.47 per share Price / Book0.14Miscellaneous Outstanding Shares963,000Free Float846,000Market Cap$2.89 million OptionableNot Optionable Beta1.57 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ISPC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iSpecimen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iSpecimen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.